UB Paderborn / Katalog / Suche / in CDI

International recommendations on the diagnosis and treatment of acquired hemophilia A

Haematologica (Roma), 2020-07, Vol.105 (7), p.1791

2020

Volltextzugriff (PDF)

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV

Blood, 2007-08, Vol.110 (3), p.815-825

2007

Volltextzugriff (PDF)

Pancreas allograft thrombosis

Transplantation, 2010-10, Vol.90 (7), p.705

2010

Volltextzugriff (PDF)

The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy

Seminars in thrombosis and hemostasis, 2016-07, Vol.42 (5), p.513

Giangrande, Paul

2016

Volltextzugriff (PDF)

Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors

British journal of haematology, 2003-06, Vol.121 (5), p.703-712

Giangrande, Paul L. F.

2003

Volltextzugriff (PDF)

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C

The Lancet (British edition), 1997-11, Vol.350 (9089), p.1425-1431

1997

Volltextzugriff (PDF)

The history of blood transfusion

British journal of haematology, 2000-09, Vol.110 (4), p.758-767

Giangrande, Paul L. F.

2000

Volltextzugriff (PDF)

Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre

Journal of laboratory physicians, 2021-09, Vol.13 (3), p.195-201

2021

Volltextzugriff (PDF)

World Federation of Haemophilia Programs in Developing Countries

Seminars in thrombosis and hemostasis, 2005-11, Vol.31 (5), p.555-560

2005

Volltextzugriff (PDF)

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

Blood, 2011-09, Vol.118 (10), p.2695-2701

2011

Volltextzugriff (PDF)

Blood products for hemophilia: past, present and future

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2004-01, Vol.18 (4), p.225-234

Giangrande, Paul L F

2004

Volltextzugriff (PDF)

Air travel and thrombosis

British journal of haematology, 2002-06, Vol.117 (3), p.509-512

GIANGRANDE, Paul L. F

2002

Volltextzugriff (PDF)

Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation

Blood, 2000-10, Vol.96 (7), p.2496-2500

2000

Volltextzugriff (PDF)

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

Journal of thrombosis and haemostasis, 2020-09, Vol.18 (S1), p.5-14

2020

Volltextzugriff (PDF)

Glad tidings for haemophilia B patients

Journal of Haemophilia Practice, 2015-03, Vol.2 (1), p.1-2

Giangrande, Paul

2015

Volltextzugriff (PDF)

Haemophilia B: Christmas disease

Expert opinion on pharmacotherapy, 2005-08, Vol.6 (9), p.1517-1524

Giangrande, Paul

2005

Volltextzugriff (PDF)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Thrombosis and haemostasis, 2017, Vol.117 (2), p.252

2017

Volltextzugriff (PDF)

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.969-978

2019

Volltextzugriff (PDF)

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.1989-1998

2015

Volltextzugriff (PDF)

HEPATITIS IN HAEMOPHILIA

British journal of haematology, 1998-10, Vol.103 (1), p.1-9

Giangrande, Paul L. F.

1998

Volltextzugriff (PDF)

Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders

British journal of haematology, 1999-12, Vol.107 (3), p.556-559

1999

Volltextzugriff (PDF)

40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

Journal of thrombosis and haemostasis, 2013-07, Vol.11 (7), p.1260-1268

2013

Volltextzugriff (PDF)

Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors

Blood reviews, 2015-06, Vol.29, p.S9-S18

2015

Volltextzugriff (PDF)

Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding

Journal of thrombosis and haemostasis, 2022-02, Vol.20 (2), p.478-485

2022

Volltextzugriff (PDF)

Mortality before and after HIV infection in the complete UK population of haemophiliacs

Nature (London), 1995-09, Vol.377 (6544), p.79-82

1995

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

International recommendations on the diagnosis and treatment of acquired hemophilia A

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV

Pancreas allograft thrombosis

The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy

Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C

The history of blood transfusion

Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre

World Federation of Haemophilia Programs in Developing Countries

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

Blood products for hemophilia: past, present and future

Air travel and thrombosis

Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

Glad tidings for haemophilia B patients

Haemophilia B: Christmas disease

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

HEPATITIS IN HAEMOPHILIA

Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders

40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors

Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding

Mortality before and after HIV infection in the complete UK population of haemophiliacs

Suchergebnisse filtern